Full Name
Dr. Bob Lowenberg MD, PhD
Job Title
Professor of Hematology
Company/Affiliation
Erasmus University Medical Center
Speaker Bio
Dr. Lowenberg is Chairman of the Department of Hematology at Erasmus University MC in Rotterdam, the Netherlands. His research activities are in the treatment and the pathobiology of leukemia, lymphoma and hematopoietic stem cell transplantation.
Dr. Löwenberg graduated with an M.D. from Groningen University, and received his Ph.D., cum laude from Erasmus University. In 1978 he was an Eleanor Roosevelt Fellow at UCLA. From to 1982 to 1990, he served as Scientific Director of the Daniel den Hoed Cancer Center, a cancer institute in the Netherlands.
In 1994, he was one of the three original founders of IntroGene (biotech company, Leiden, which became Crucell and is now part of Johnson & Johnson). Dr. Löwenberg co-founded Skyline Diagnostics B.V. in 2005 and served as its Chief Scientific Officer. In 2018 he was also a co-founder of the cancer immunotherapy company Frame Therapeutics. From 2013-2015, he served as the first non-American Editor-in-Chief of Blood, the Journal of the American Society of Hematology.
He has been a member of the Scientific Advisory Board at AIMM Therapeutics BV since June 20, 2013, and serves on the editorial board of several international journals, including The New England Journal of Medicine. He founded the Dutch-Belgian Cooperative Group on Hemato-Oncology in Adults (HOVON Cooperative Group), and served as chair of the HOVON leukemia trial group. He was the Founder of European Hematology Association (EHA) and served as its President. He also served as President of the International Society of Experimental Hematology and the International Society of Hematology. He serves as Member at the Royal Academy of Sciences and Arts of The Netherlands and is Chairman of the Medical Advisory Council of the Dutch Royal Academy of Arts and Sciences.
In 2004, Dr. Löwenberg received the Dr. P. Muntendam Cancer Prize of the Netherlands Cancer Society, and in 2006 he received the Jacqueline Seroussi Memorial Foundation for Cancer Research Award for his scientific contributions in the field of leukemia.
Dr. Löwenberg graduated with an M.D. from Groningen University, and received his Ph.D., cum laude from Erasmus University. In 1978 he was an Eleanor Roosevelt Fellow at UCLA. From to 1982 to 1990, he served as Scientific Director of the Daniel den Hoed Cancer Center, a cancer institute in the Netherlands.
In 1994, he was one of the three original founders of IntroGene (biotech company, Leiden, which became Crucell and is now part of Johnson & Johnson). Dr. Löwenberg co-founded Skyline Diagnostics B.V. in 2005 and served as its Chief Scientific Officer. In 2018 he was also a co-founder of the cancer immunotherapy company Frame Therapeutics. From 2013-2015, he served as the first non-American Editor-in-Chief of Blood, the Journal of the American Society of Hematology.
He has been a member of the Scientific Advisory Board at AIMM Therapeutics BV since June 20, 2013, and serves on the editorial board of several international journals, including The New England Journal of Medicine. He founded the Dutch-Belgian Cooperative Group on Hemato-Oncology in Adults (HOVON Cooperative Group), and served as chair of the HOVON leukemia trial group. He was the Founder of European Hematology Association (EHA) and served as its President. He also served as President of the International Society of Experimental Hematology and the International Society of Hematology. He serves as Member at the Royal Academy of Sciences and Arts of The Netherlands and is Chairman of the Medical Advisory Council of the Dutch Royal Academy of Arts and Sciences.
In 2004, Dr. Löwenberg received the Dr. P. Muntendam Cancer Prize of the Netherlands Cancer Society, and in 2006 he received the Jacqueline Seroussi Memorial Foundation for Cancer Research Award for his scientific contributions in the field of leukemia.
Speaking At
